PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Res… (NCT06665100) | Clinical Trial Compass
RecruitingPhase 2
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
United States100 participantsStarted 2025-06-27
Plain-language summary
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subjects with hematologic malignancies (i.e., leukemia, lymphoma, or multiple myeloma) or recipients of an allogeneic or autologous hematopoietic stem cell transplantation for one of the following diagnoses: leukemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, and myelodysplastic and myeloproliferative disorder.
✓. Subjects who have undergone active cytotoxic chemotherapy within 6 months or subjects who are on an immunosuppressive therapy (e.g., alemtuzumab, ibrutinib, mycophenolate mofetil, corticosteroids ≥1mg/kg prednisone equivalent).
✓. Subjects who are recipients of an allogeneic hematopoietic stem cell transplant (HSCT) must be deemed high risk with an Immunodeficiency Scoring Index (ISI) , of greater or equal to 4.
✓. Subjects who are recipients of an autologous HSCT must be within 3 months of the transplant procedure.
✓. Subjects must be symptomatic with upper or lower respiratory tract symptoms such as rhinorrhea, sore throat or cough and must be dosed within 6 days from the onset of symptoms.
✓. Chest X-ray with a Radiologic Severity Index (RSI) score of 6 or lower.
✓. Subjects must have pulse oximetry of hemoglobin saturation ≥ 93% on room air.
✓. Spirometry (forced expiratory volume in one second \[FEV1\] and forced vital capacity \[FVC\]) ≥70% of predicted value.
Exclusion criteria
✕. Patients with a pulse oximetry of hemoglobin saturation less than 93% on room air.
What they're measuring
1
Efficacy of PUL-042 Inhalation Solution on Lower Respiratory Tract Complications (LRTC)
. Known history of chronic pulmonary disease (e.g., asthma \[including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection\], chronic pulmonary disease, pulmonary fibrosis, COPD), pulmonary hypertension, or heart failure.
✕. Subjects treated for fungal, viral, or bacterial pneumonia in the previous 30 days.
✕. Exposure to any investigational agent (defined as any non-FDA-approved agent) within 30 days, or 5 half-lives of the investigational agent, whichever is longer, prior to the Screening Visit.
✕. Allogeneic HSCT recipients with an ISI of 3 or less.
✕. Autologous HSCT recipients more than 3 months after the transplant procedure.
✕. Patients with a relapsed and/or refractory underlying hematologic malignancy with a life expectancy of less than 2 months.
✕. HSCT recipients in the pre-engraftment period.